IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Axonics Modulation Technologies has pulled in a meaty IPO as it looks to compete with medical technology major Medtronic for its neuromodulation device in overactive bladder (OAB). The IPO window has ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ® ...

Ladies and gentlemen, thank you for standing by. Welcome to the Axonics Third Quarter 2023 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

Barely 6 months after raising a $38.5 million Series B to advance its neuromodulation implant to treat overactive bladder and fecal dysfunction, Axonics Modulation Technologies won a CE mark for the ...

Axonics Modulation Technologies Inc., a urology-focused medical device maker, is growing in size and reputation, along with its market. The Irvine firm (Nasdaq: AXNX), which went public two years ago ...

Thank you for standing by and welcome to the Axonics' First Quarter 2023 Results Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will ...